Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
作者信息
Hummel Julia, Kullmann Stephanie, Heni Martin
机构信息
Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, 72076 Tübingen, Germany.
German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.
出版信息
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3080-e3081. doi: 10.1210/clinem/dgac179.
Abstract
摘要
相似文献
1
Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3080-e3081. doi: 10.1210/clinem/dgac179.
2
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.达格列净和艾塞那肽联合治疗对 2 型糖尿病患者食物线索诱导的大脑激活的影响。
J Clin Endocrinol Metab. 2022 May 17;107(6):e2590-e2599. doi: 10.1210/clinem/dgac043.
3
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.利拉鲁肽与达格列净联合治疗可降低 2 型糖尿病患者对美味食物的预期和摄入的大脑反应：一项随机对照试验。
Diabetes Obes Metab. 2022 Aug;24(8):1588-1597. doi: 10.1111/dom.14732. Epub 2022 May 23.
4
Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.大脑对低热量食物图片的反应：达格列净和艾塞那肽随机试验的探索性分析。
Front Endocrinol (Lausanne). 2022 May 4;13:863592. doi: 10.3389/fendo.2022.863592. eCollection 2022.
5
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.每周一次艾塞那肽加每日一次达格列净对比二甲双胍单药治疗控制不佳的 2 型糖尿病患者中单独使用艾塞那肽或达格列净（DURATION-8）：一项 28 周、多中心、双盲、3 期、随机对照试验。
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16.
6
Bolstering your armamentarium with SGLT2 inhibitors.用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂充实你的治疗手段。
Nurse Pract. 2017 Oct 18;42(10):28-34. doi: 10.1097/01.NPR.0000524665.16846.63.
7
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.每日两次艾塞那肽与达格列净单药及联合治疗肥胖 2 型糖尿病患者肾功能标志物的影响：一项随机对照临床试验的预设二次分析。
Diabetes Obes Metab. 2021 Aug;23(8):1851-1858. doi: 10.1111/dom.14410. Epub 2021 May 14.
8
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病合并非酒精性脂肪性肝病患者血清可溶性二肽基肽酶-4水平的影响。
Int J Clin Pract. 2019 May;73(5):e13335. doi: 10.1111/ijcp.13335. Epub 2019 Apr 1.
9
Dapagliflozin for heart failure: is it a class effect?达格列净用于治疗心力衰竭：这是一种类效应吗？
Future Cardiol. 2021 Mar;17(2):355-361. doi: 10.2217/fca-2020-0087. Epub 2020 Aug 5.
10
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.从 DAPA-HF 试验中吸取的有关 SGLT2 抑制剂在其他即将完成的大规模试验背景下对心力衰竭事件的获益机制的经验教训。
Cardiovasc Diabetol. 2019 Oct 4;18(1):129. doi: 10.1186/s12933-019-0938-6.
引用本文的文献
1
The insulin resistant brain: impact on whole-body metabolism and body fat distribution.胰岛素抵抗的大脑：对全身代谢和体脂肪分布的影响。
Diabetologia. 2024 Jul;67(7):1181-1191. doi: 10.1007/s00125-024-06104-9. Epub 2024 Feb 16.
本文引用的文献
1
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.达格列净和艾塞那肽联合治疗对 2 型糖尿病患者食物线索诱导的大脑激活的影响。
J Clin Endocrinol Metab. 2022 May 17;107(6):e2590-e2599. doi: 10.1210/clinem/dgac043.
2
Neuroprotective Effect of SGLT2 Inhibitors.SGLT2 抑制剂的神经保护作用。
Molecules. 2021 Nov 28;26(23):7213. doi: 10.3390/molecules26237213.
3
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.恩格列净可改善糖尿病前期患者下丘脑的胰岛素敏感性：一项随机、双盲、安慰剂对照、2 期临床试验。
Diabetes Care. 2022 Feb 1;45(2):398-406. doi: 10.2337/dc21-1136.
4
GLP-1 physiology informs the pharmacotherapy of obesity.GLP-1 生理学为肥胖症的药物治疗提供了依据。
Mol Metab. 2022 Mar;57:101351. doi: 10.1016/j.molmet.2021.101351. Epub 2021 Oct 6.
5
Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities.2 型糖尿病与认知功能障碍——有效管理这两种共病。
Lancet Diabetes Endocrinol. 2020 Jun;8(6):535-545. doi: 10.1016/S2213-8587(20)30118-2.
6
Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study.降糖药物与 2 型糖尿病患者痴呆风险的关系：一项巢式病例对照研究。
Eur J Endocrinol. 2019 Nov;181(5):499-507. doi: 10.1530/EJE-19-0259.
7
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology.钠-葡萄糖协同转运蛋白及其抑制剂：临床生理学。
Cell Metab. 2017 Jul 5;26(1):27-38. doi: 10.1016/j.cmet.2017.04.011. Epub 2017 May 11.
Zotero 插件